99 related articles for article (PubMed ID: 11448536)
21. Transactivational and DNA binding abilities of endogenous p53 in p53 mutant cell lines.
Park DJ; Nakamura H; Chumakov AM; Said JW; Miller CW; Chen DL; Koeffler HP
Oncogene; 1994 Jul; 9(7):1899-906. PubMed ID: 8208536
[TBL] [Abstract][Full Text] [Related]
22. p53 mutations in sporadic adrenocortical tumors.
Ohgaki H; Kleihues P; Heitz PU
Int J Cancer; 1993 May; 54(3):408-10. PubMed ID: 8509216
[TBL] [Abstract][Full Text] [Related]
23. p53 protein and its messenger ribonucleic acid in human adrenal tumors.
Adleff V; Rácz K; Tóth M; Varga I; Bezzegh A; Gláz E
J Endocrinol Invest; 1998 Dec; 21(11):753-7. PubMed ID: 9972675
[TBL] [Abstract][Full Text] [Related]
24. The relatively high frequency of p53 gene mutations in multiple and malignant phaeochromocytomas.
Yoshimoto T; Naruse M; Zeng Z; Nishikawa T; Kasajima T; Toma H; Yamamori S; Matsumoto H; Tanabe A; Naruse K; Demura H
J Endocrinol; 1998 Nov; 159(2):247-55. PubMed ID: 9795365
[TBL] [Abstract][Full Text] [Related]
25. The human p53 gene mutated at position 249 per se is not sufficient to immortalize human liver cells.
Schleger C; Becker R; Oesch F; Steinberg P
Hepatology; 1999 Mar; 29(3):834-8. PubMed ID: 10051487
[TBL] [Abstract][Full Text] [Related]
26. Transforming activity of mutant human p53 alleles.
Slingerland JM; Benchimol S
J Cell Physiol; 1991 Sep; 148(3):391-5. PubMed ID: 1918170
[TBL] [Abstract][Full Text] [Related]
27. mRNA and protein expression of p53 mutations in human bladder cancer cell lines.
Kawasaki T; Tomita Y; Watanabe R; Tanikawa T; Kumanishi T; Sato S
Cancer Lett; 1994 Jul; 82(1):113-21. PubMed ID: 8033064
[TBL] [Abstract][Full Text] [Related]
28. Decreased GTPase activity of K-ras mutants deriving from human functional adrenocortical tumours.
Lin SR; Hsu CH; Tsai JH; Wang JY; Hsieh TJ; Wu CH
Br J Cancer; 2000 Mar; 82(5):1035-40. PubMed ID: 10737386
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of the chemosensitivity of head and neck cancer cells based on the diverse function of mutated-p53.
Shinagawa Y; Kawamata H; Omotehara F; Nakashiro K; Hoque MO; Furihata T; Horiuchi H; Imai Y; Fujimori T; Fujibayashi T
Int J Oncol; 2003 Feb; 22(2):383-9. PubMed ID: 12527938
[TBL] [Abstract][Full Text] [Related]
30. [The expression and localization of wild-type p53-GFP fused gene on human high-metastasis hepatocellular carcinoma cell line].
He P; Tang Z; Ye S
Zhonghua Gan Zang Bing Za Zhi; 2000 Apr; 8(2):105-7. PubMed ID: 10861118
[TBL] [Abstract][Full Text] [Related]
31. Steroidogenic factor 1 (SF-1) and SP1 are required for regulation of bovine CYP11A gene expression in bovine luteal cells and adrenal Y1 cells.
Liu Z; Simpson ER
Mol Endocrinol; 1997 Feb; 11(2):127-37. PubMed ID: 9013760
[TBL] [Abstract][Full Text] [Related]
32. [Molecular biology of incidentally diagnosed adrenal gland space-occupying lesion].
Reincke M; Allolio B
Zentralbl Chir; 1997; 122(6):430-7. PubMed ID: 9334108
[TBL] [Abstract][Full Text] [Related]
33. Mutational analysis of StAR gene in adrenal tumors.
Stigliano A; Caiola S; Siniscalchi E; Papini E; Crescenzi A; Monti S; Arnaldi G; Mantero F; Sciarra F; Toscano V
Int J Cancer; 2002 Jan; 97(3):357-60. PubMed ID: 11774288
[TBL] [Abstract][Full Text] [Related]
34. Tumor-derived p53 mutants induce oncogenesis by transactivating growth-promoting genes.
Scian MJ; Stagliano KE; Deb D; Ellis MA; Carchman EH; Das A; Valerie K; Deb SP; Deb S
Oncogene; 2004 May; 23(25):4430-43. PubMed ID: 15077194
[TBL] [Abstract][Full Text] [Related]
35. Initiation of human astrocytoma by clonal evolution of cells with progressive loss of p53 functions in a patient with a 283H TP53 germ-line mutation: evidence for a precursor lesion.
Fulci G; Ishii N; Maurici D; Gernert KM; Hainaut P; Kaur B; Van Meir EG
Cancer Res; 2002 May; 62(10):2897-905. PubMed ID: 12019170
[TBL] [Abstract][Full Text] [Related]
36. Transcriptional activation by p53 correlates with suppression of growth but not transformation.
Crook T; Marston NJ; Sara EA; Vousden KH
Cell; 1994 Dec; 79(5):817-27. PubMed ID: 8001119
[TBL] [Abstract][Full Text] [Related]
37. Wild-type p53 and a p53 temperature-sensitive mutant suppress human soft tissue sarcoma by enhancing cell cycle control.
Pollock R; Lang A; Ge T; Sun D; Tan M; Yu D
Clin Cancer Res; 1998 Aug; 4(8):1985-94. PubMed ID: 9717829
[TBL] [Abstract][Full Text] [Related]
38. Patches of mutant p53-immunoreactive epidermal cells induced by chronic UVB Irradiation harbor the same p53 mutations as squamous cell carcinomas in the skin of hairless SKH-1 mice.
Kramata P; Lu YP; Lou YR; Singh RN; Kwon SM; Conney AH
Cancer Res; 2005 May; 65(9):3577-85. PubMed ID: 15867351
[TBL] [Abstract][Full Text] [Related]
39. p53 mutations in human adrenocortical neoplasms: immunohistochemical and molecular studies.
Reincke M; Karl M; Travis WH; Mastorakos G; Allolio B; Linehan HM; Chrousos GP
J Clin Endocrinol Metab; 1994 Mar; 78(3):790-4. PubMed ID: 8126158
[TBL] [Abstract][Full Text] [Related]
40. p53 mutation and tamoxifen resistance in breast cancer.
Elledge RM; Lock-Lim S; Allred DC; Hilsenbeck SG; Cordner L
Clin Cancer Res; 1995 Oct; 1(10):1203-8. PubMed ID: 9815913
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
